Author

Naruhito Takenaka

Observed name: N. Takenaka

Institution: Taiho Pharmaceutical (Japan)

Observed institution: Taiho Pharmaceutical (Japan)

ORCID: 0009-0000-7746-6982

Observed ORCID: 0009-0000-7746-6982

OpenAlex ID: A5019390917

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

2023 · Yasutoshi Kuboki, Tetsuji Terazawa, et al. · British Journal of Cancer · 20

S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial

2019 · Eiji Sunami, Tetsuya Kusumoto, et al. · Clinical Colorectal Cancer · 16

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy

2018 · Takayuki Yoshino, Eiji Oki, et al. · ESMO Open · 14

Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial

2020 · Yasuhide Yamada, Kei Muro, et al. · Global Health & Medicine · 9

S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial

2021 · J. Watanabe, S. Sasaki, et al. · ESMO Open · 8

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

2024 · Yu Sunakawa, Yasutoshi Kuboki, et al. · Targeted Oncology · 4

TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.

2018 · Takayuki Yoshino, Eiji Oki, et al. · Journal of Clinical Oncology · 1

Works count: 7

Citation count: 72

H-index: 5

I10-index: 3